Logo image of EW

EDWARDS LIFESCIENCES CORP (EW) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:EW - US28176E1082 - Common Stock

85.14 USD
+1.68 (+2.01%)
Last: 1/21/2026, 3:42:35 PM
85.05 USD
-0.09 (-0.11%)
After Hours: 1/21/2026, 3:42:35 PM
Fundamental Rating

7

EW gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. EW scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EW is not valued too expensively and it also shows a decent growth rate. This makes EW very considerable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year EW was profitable.
  • In the past year EW had a positive cash flow from operations.
  • EW had positive earnings in each of the past 5 years.
  • EW had a positive operating cash flow in each of the past 5 years.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 10.31%, EW belongs to the top of the industry, outperforming 94.62% of the companies in the same industry.
  • EW has a Return On Equity of 13.40%. This is amongst the best in the industry. EW outperforms 89.25% of its industry peers.
  • EW has a Return On Invested Capital of 12.50%. This is amongst the best in the industry. EW outperforms 93.01% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for EW is significantly above the industry average of 8.84%.
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROIC 12.5%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • EW's Profit Margin of 23.25% is amongst the best of the industry. EW outperforms 94.62% of its industry peers.
  • EW's Profit Margin has improved in the last couple of years.
  • EW has a Operating Margin of 27.73%. This is amongst the best in the industry. EW outperforms 96.24% of its industry peers.
  • EW's Operating Margin has been stable in the last couple of years.
  • With an excellent Gross Margin value of 78.19%, EW belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
  • EW's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so EW is still creating some value.
  • Compared to 1 year ago, EW has less shares outstanding
  • EW has less shares outstanding than it did 5 years ago.
  • EW has a better debt/assets ratio than last year.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 12.25 indicates that EW is not in any danger for bankruptcy at the moment.
  • EW's Altman-Z score of 12.25 is amongst the best of the industry. EW outperforms 89.25% of its industry peers.
  • EW has a debt to FCF ratio of 0.75. This is a very positive value and a sign of high solvency as it would only need 0.75 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.75, EW belongs to the top of the industry, outperforming 90.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.06 indicates that EW is not too dependend on debt financing.
  • EW has a Debt to Equity ratio of 0.06. This is in the better half of the industry: EW outperforms 67.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Altman-Z 12.25
ROIC/WACC1.25
WACC10.02%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 4.00 indicates that EW has no problem at all paying its short term obligations.
  • EW has a Current ratio of 4.00. This is in the better half of the industry: EW outperforms 69.35% of its industry peers.
  • A Quick Ratio of 3.29 indicates that EW has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.29, EW is in the better half of the industry, outperforming 68.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 3.29
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

5

3. Growth

3.1 Past

  • EW shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.75%.
  • Measured over the past 5 years, EW shows a small growth in Earnings Per Share. The EPS has been growing by 7.13% on average per year.
  • Looking at the last year, EW shows a small growth in Revenue. The Revenue has grown by 4.67% in the last year.
  • EW shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.58% yearly.
EPS 1Y (TTM)-3.75%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%0%
Revenue 1Y (TTM)4.67%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%14.67%

3.2 Future

  • Based on estimates for the next years, EW will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.40% on average per year.
  • The Revenue is expected to grow by 8.47% on average over the next years. This is quite good.
EPS Next Y1.27%
EPS Next 2Y6.3%
EPS Next 3Y7.79%
EPS Next 5Y9.4%
Revenue Next Year4.68%
Revenue Next 2Y7.17%
Revenue Next 3Y8.07%
Revenue Next 5Y8.47%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 33.13, EW can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, EW is valued a bit cheaper than the industry average as 73.12% of the companies are valued more expensively.
  • EW is valuated rather expensively when we compare the Price/Earnings ratio to 26.94, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 28.76, EW can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 73.66% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.94. EW is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 33.13
Fwd PE 28.76
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 73.12% of the companies in the same industry are more expensive than EW, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 72.04% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 61.79
EV/EBITDA 24.62
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • EW has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)26.15
PEG (5Y)4.65
EPS Next 2Y6.3%
EPS Next 3Y7.79%

0

5. Dividend

5.1 Amount

  • EW does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

EDWARDS LIFESCIENCES CORP

NYSE:EW (1/21/2026, 3:42:35 PM)

After market: 85.05 -0.09 (-0.11%)

85.14

+1.68 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30
Earnings (Next)02-10
Inst Owners89.94%
Inst Owner Change0.09%
Ins Owners0.11%
Ins Owner Change-1.3%
Market Cap49.41B
Revenue(TTM)5.88B
Net Income(TTM)1.37B
Analysts79.52
Price Target97.99 (15.09%)
Short Float %1.25%
Short Ratio2.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.01%
Min EPS beat(2)4.4%
Max EPS beat(2)9.63%
EPS beat(4)4
Avg EPS beat(4)5.38%
Min EPS beat(4)3.4%
Max EPS beat(4)9.63%
EPS beat(8)5
Avg EPS beat(8)2.27%
EPS beat(12)6
Avg EPS beat(12)1.21%
EPS beat(16)7
Avg EPS beat(16)-0.18%
Revenue beat(2)1
Avg Revenue beat(2)0.37%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.85%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)2
Avg Revenue beat(12)-2.12%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)2.26%
PT rev (3m)9.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.81%
EPS NY rev (1m)-0.24%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 33.13
Fwd PE 28.76
P/S 8.4
P/FCF 61.79
P/OCF 48.59
P/B 4.84
P/tB 6.76
EV/EBITDA 24.62
EPS(TTM)2.57
EY3.02%
EPS(NY)2.96
Fwd EY3.48%
FCF(TTM)1.38
FCFY1.62%
OCF(TTM)1.75
OCFY2.06%
SpS10.14
BVpS17.59
TBVpS12.59
PEG (NY)26.15
PEG (5Y)4.65
Graham Number31.89
Profitability
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROCE 13.97%
ROIC 12.5%
ROICexc 18.63%
ROICexgc 29.56%
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
FCFM 13.59%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
ROICexc(3y)20.51%
ROICexc(5y)22.13%
ROICexgc(3y)29.09%
ROICexgc(5y)31.03%
ROCE(3y)17.66%
ROCE(5y)19.29%
ROICexgc growth 3Y-5.47%
ROICexgc growth 5Y-8.01%
ROICexc growth 3Y-11.82%
ROICexc growth 5Y-8.6%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Debt/EBITDA 0.33
Cap/Depr 138.79%
Cap/Sales 3.69%
Interest Coverage 250
Cash Conversion 56.86%
Profit Quality 58.45%
Current Ratio 4
Quick Ratio 3.29
Altman-Z 12.25
F-Score6
WACC10.02%
ROIC/WACC1.25
Cap/Depr(3y)185.14%
Cap/Depr(5y)236.01%
Cap/Sales(3y)5.48%
Cap/Sales(5y)6.41%
Profit Quality(3y)37.92%
Profit Quality(5y)57.13%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.75%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%0%
EPS Next Y1.27%
EPS Next 2Y6.3%
EPS Next 3Y7.79%
EPS Next 5Y9.4%
Revenue 1Y (TTM)4.67%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%14.67%
Revenue Next Year4.68%
Revenue Next 2Y7.17%
Revenue Next 3Y8.07%
Revenue Next 5Y8.47%
EBIT growth 1Y4.68%
EBIT growth 3Y-4.72%
EBIT growth 5Y3.49%
EBIT Next Year13%
EBIT Next 3Y12.27%
EBIT Next 5Y12.3%
FCF growth 1Y1.45%
FCF growth 3Y-42.99%
FCF growth 5Y-22.01%
OCF growth 1Y-2.42%
OCF growth 3Y-32.1%
OCF growth 5Y-14.39%

EDWARDS LIFESCIENCES CORP / EW FAQ

What is the fundamental rating for EW stock?

ChartMill assigns a fundamental rating of 7 / 10 to EW.


What is the valuation status for EW stock?

ChartMill assigns a valuation rating of 4 / 10 to EDWARDS LIFESCIENCES CORP (EW). This can be considered as Fairly Valued.


How profitable is EDWARDS LIFESCIENCES CORP (EW) stock?

EDWARDS LIFESCIENCES CORP (EW) has a profitability rating of 9 / 10.


What is the earnings growth outlook for EDWARDS LIFESCIENCES CORP?

The Earnings per Share (EPS) of EDWARDS LIFESCIENCES CORP (EW) is expected to grow by 1.27% in the next year.